Occam is pleased to announce the placement of Gino Van Heeke as CSO of LabGenius, a machine learning (ML)-driven protein engineering company. In this role, Gino will leverage his wealth of drug discovery and development experience to direct LabGenius’ scientific strategy. 

Van Heeke has forged a richly variegated career spanning large and small companies where his focus has cut across both large and small molecule drug discovery & development. His demonstrated success building and leading dynamic scientific teams in myriad settings coupled with translational creativity and entrepreneurial verve will serve LabGenius well as it seeks to automate large molecule drug discovery.

Van Heeke joins LabGenius from Engitix Therapeutics, where, as CSO, he established a portfolio of projects and initiated the company’s first drug discovery campaign. Before this, Gino was Senior Director, Discovery and Early Development at Ablynx where he led the discovery of NANOBODY® drug candidates and their transition to clinical development. Prior to his move into biotech, Gino held several senior positions at Novartis Institutes for Biomedical Research over a 22-year tenure, including Executive Director for Biologics.

Dr. Edwin Moses, LabGenius Chairman commented “Gino’s expertise in translational research, coupled with LabGenius’ ML-driven drug discovery platform, is an excellent combination which I believe will further accelerate the company’s successful development.”